4-(4-chloro-benzylsulfanyl)-phenylamine | 103977-34-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-(4-chloro-benzylsulfanyl)-phenylamine
• 英文别名: 4-[(4-Chlorobenzyl)sulfanyl]aniline；4-[(4-chlorophenyl)methylsulfanyl]aniline
• CAS: 103977-34-0
• 化学式: C₁₃H₁₂ClNS
• mdl: MFCD02755408
• 分子量: 249.764
• InChiKey: QXVCMXMHZFXHSG-UHFFFAOYSA-N

物化性质

• 沸点：
  414.0±30.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-chloro-benzylsulfanyl)-phenylamine 在 盐酸 、 硫酸 、 sodium acetate 、 溶剂黄146 、 巯基乙酸 、 sodium nitrite 作用下， 反应 11.25h， 生成 2-[4-(4-Chloro-benzylsulfanyl)-phenyl]-2H-[1,2,4]triazine-3,5-dione
  参考文献：
  名称：

  6-氮杂尿嘧啶的抗球虫衍生物。4.苯基硫醚和苯基砜侧链的效价提高了1000倍。

  摘要：

  我们报道了在利用我们较早的发现中的进一步进展，即当适当取代的苄基或苯基连接在N-1处时，6-氮杂嘧啶的抗球虫活性显着增加。在先前的结构-活性关系和多重线性回归分析的指导下，制备了含有苯砜或苯硫醚侧链的6-氮杂嘧啶。这些可以防止鸡中按重量计最低抑菌浓度的球虫球菌感染，其最低抑菌浓度为0.25 ppm（重量），比6-氮杂尿嘧啶提高了4000倍，并且血浆半衰期比早期有效的类似物短。硫化物比砜更有效，尽管它们在体内迅速被氧化成砜。

  DOI：

  10.1021/jm00143a015
• 作为产物：
  描述：

  4-硝基苯硫醇 在 铁粉 、 potassium carbonate 、 溶剂黄146 作用下， 以 水 为溶剂， 生成 4-(4-chloro-benzylsulfanyl)-phenylamine
  参考文献：
  名称：

  结晶学，定量构效关系与分子图形学，比较分析4,6-二氨基-1,2-二氢-2,2-二甲基-1-（取代）对鸡肝和干酪乳杆菌中二氢叶酸还原酶的抑制作用-苯基）-s-三嗪s。

  摘要：

  已经研究了用4，6-二氨基-1，2-二氢-2，2-二甲基-1-（取代的苯基）-s-三嗪对鸡肝和干酪乳杆菌中二氢叶酸还原酶的抑制作用。发现对于鸡肉酶，通过以下方程式关联101种三嗪的抑制剂效能：log 1 / Kiapp = 0.85 sigma tau'-1.04 log（beta X 10 sigma tau'+ 1）+ 0.57 sigma + 6.36。参数tau'表示对于某些取代基，tau =0。就干酪乳杆菌DHFR结果而言，间位和对位导数不能包含在同一方程式中。对于38个间位取代的化合物，发现log 1 / Kiapp = 0.38 tau'3-0.91 log（βX 10 tau'3 + 1）+ 0.71I + 4.60，对于32个对位取代的苯基三嗪log 1 / Kiapp = 0.44 tau'4-0.65 log（βtau'4 + 1'）-0.90 upsilon + 0

  DOI：

  10.1021/jm00368a006

文献信息

• Substituted heteroaryl- and phenylsulfamoyl compounds
  申请人：Hamanaka S. Ernest

  公开号：US20050228015A1

  公开（公告）日：2005-10-13

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环和苯基磺酰胺化合物，含有这些化合物的制药组合物以及将这些化合物用作过氧化物酶增殖子激活受体（PPAR）激动剂。PPARα激动剂，含有这些化合物的制药组合物以及使用这些化合物以提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗由低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Substituted Heteroaryl- and Phenylsulfamoyl Compounds
  申请人：Hamanaka S. Ernest

  公开号：US20060258723A1

  公开（公告）日：2006-11-16

  The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator actuator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯磺酰胺化合物，含有这种化合物的制药组合物以及将这种化合物用作过氧化物酶体增殖激活受体（PPAR）激动剂。PPARα激动剂，含有这种化合物的制药组合物以及将这种化合物用于升高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低某些其他血浆脂质水平，如LDL胆固醇和甘油三酯，因此治疗低HDL胆固醇水平和/或高LDL胆固醇和甘油三酯水平加剧的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中使用。这些化合物也适用于治疗反式能量平衡（NEB）和反刍动物相关疾病。
• Novel fungicidal benzylsulfanyl-phenylguanidines
  作者：Karin Thevissen、Klaartje Pellens、Katrijn De Brucker、Isabelle E.J.A. François、Kwok K. Chow、Els M.K. Meert、Wim Meert、Geert Van Minnebruggen、Marcel Borgers、Valérie Vroome、Jeremy Levin、Dirk De Vos、Louis Maes、Paul Cos、Bruno P.A. Cammue

  DOI：10.1016/j.bmcl.2011.04.075

  日期：2011.6

  A series of substituted benzylsulfanyl-phenylamines was synthesized, of which four substituted benzylsulfanyl-phenylguanidines (665, 666, 667 and 684) showed potent fungicidal activity (minimal fungicidal concentration, MFC <= 10 mu M for Candida albicans and Candida glabrata). A benzylsulfanyl-phenyl scaffold with an unsubstituted guanidine resulted in less active compounds (MFC = 50-100 mu M), whereas substitution with an unsubstituted amine group resulted in compounds without fungicidal activity. Compounds 665, 666, 667 and 684 also showed activity against single C. albicans biofilms and biofilms consisting of C. albicans and Staphylococcus epidermidis (minimal concentration resulting in 50% eradication of the biofilm, BEC50 <= 121 mu M for both biofilm setups). Compounds 665 and 666 combined potent fungicidal (MFC = 5 mu M) and bactericidal activity (minimal bactericidal concentration, MBC for S. epidermidis <= 4 mu M). In an in vivo Caenorhabditis elegans model, compounds 665 and 667 exhibited less toxicity than 666 and 684. Moreover, addition of those compounds to Candida-infected C. elegans cultures resulted in increased survival of Candida-infected worms, demonstrating their in vivo efficacy in a mini-host model. (C) 2011 Elsevier Ltd. All rights reserved.
• Atom-Economic Synthesis of Functionalized Octahydroacridines from Citronellal or 3-(Phenylthio)-citronellal
  作者：Raquel G. Jacob、Márcio S. Silva、Samuel R. Mendes、Elton L. Borges、Eder J. Lenardão、Gelson Perin

  DOI：10.1080/00397910802663469

  日期：2009.7.7

  Here we present a simple, solvent-free, one-pot, hetero-Diels-Alder reaction of (R)-citronellal or 3-(phenylthio)-citronellal with arylamines using solid-supported catalyst (SiO2/ZnCl2). This general, efficient, and improved method is selective, affording preferentially new trans-fused 3-(phenylthio)-octahydroacridines (S-OHAs) in good yields. The use of microwave irradiation facilitates the procedure and accelerates the reaction.
• US7262318B2
  申请人：——

  公开号：US7262318B2

  公开（公告）日：2007-08-28